Per ulteriori informazioni selezionare i riferimenti di interesse.
High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma
Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma
JOURNAL OF CLINICAL ONCOLOGY
LYMPHOCYTE TRANSFUSION THERAPY FOR CANCER-PATIENTS